Cipla Ltd News
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation
 "RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead")
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 observations and adverse outcomes
 "Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows")
NTPC, PFC: 5 F&O stocks see long OI build-up; Here's how to trade in them
Build-up of long OI in general indicates that traders are expecting the price of the underlying stock or index to gain in the near-term.
 "NTPC, PFC: 5 F&O stocks see long OI build-up; Here's how to trade in them")
Analysts turn cautious on Cipla as US FDA action delays key US launches
Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant
 "Analysts turn cautious on Cipla as US FDA action delays key US launches")
Cipla falls 4%, nears 52-week low on concerns of product launch delay in US
In the past seven trading days, the stock has dipped 11% after the United States Food and Drug Administration issued Form 483 with 8 observations for the company's Pithampur manufacturing facilities
 "Cipla falls 4%, nears 52-week low on concerns of product launch delay in US")
Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low
Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts
 "Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low")
Cipla dips 7% after Pithampur unit receives 8 USFDA observations
The company said it will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
 "Cipla dips 7% after Pithampur unit receives 8 USFDA observations")
Cipla Q3 net up 10% to Rs 801 cr, posts highest ever quarterly sales in US
Revenue up 6% to Rs 5,810 cr; firm expects US FDA audit at Goa unit
Cipla launches diagnostic device, says it will provide results in minutes
Cippoint offers parameters to test for cardiac markers, diabetes, infectious diseases, fertility
 "Cipla launches diagnostic device, says it will provide results in minutes")
Stocks to Watch: Elin Electronics, Cipla, Eicher Motors, RIL, Banks, Pharma
Stocks to Watch: Elin Electronics to debut today, the stock is likely to list on a quiet note.
 "Stocks to Watch: Elin Electronics, Cipla, Eicher Motors, RIL, Banks, Pharma")
Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%
Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.
 "Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%")
Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate
The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately
